Canandaigua National Trust Co of Florida buys AbbVie stake; drug receives BT designation
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Canandaigua National Trust Co of Florida purchased 2,664 shares of AbbVie stock, valued at approximately $697,000, during the third quarter, according to a Form 13F filing. Separately, AbbVie secured Breakthrough Therapy Designation for one of its drugs.
From dailypolitical.com
Why it matters
The Breakthrough Therapy Designation from the FDA may accelerate the drug's development and market potential. The investment by Canandaigua National Trust Co of Florida reflects activity among institutional investors in AbbVie.
From dailypolitical.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
AbbVie might see increased revenue potential due to the Breakthrough Therapy Designation, which could accelerate drug development and market entry.
Keep exploring
The entities involved
Related events
- AbbVie reached an agreement for a drug in Canada.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- AbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.